 GSK PLC LSE:GSK, NYSE:GSK has been upgraded by Credit Suisse on the assumption that its potential liability for Zantac lawsuits will be much smaller than the US12bn that has been wiped from its market cap in recent weeks. The Swiss bank swapped its sell rating for a hold but trimmed the share price target to 1,430p from 1,630p to reflect a US5bn base-case of liability costs from Zantac. 